← back to search

Marcelo Silva

Universidade Federal da Bahia · BR
Area of research
Epidemiology · Hepatology
Research interest
Research interests include Hepatitis C virus research, Liver Disease Diagnosis and Treatment, Hepatitis B Virus Studies, and Liver Disease and Transplantation.
h-index
29
citations
10,393
works
130
NIH funding
primary concept
Medicine
email

Recent publications

The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease
JHEP Reports 2024cited by 29position: middledoi
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Hepatology 2023cited by 2,786position: middledoi
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Journal of Hepatology 2023cited by 2,592position: middledoi
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Annals of Hepatology 2023cited by 781position: middledoi
Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease
Journal of Hepatology 2023cited by 94position: middledoi
A global action agenda for turning the tide on fatty liver disease
Hepatology 2023cited by 83position: middledoi
Effects of immunosuppressive drugs on COVID‐19 severity in patients with autoimmune hepatitis
Liver International 2021cited by 40position: middledoi
Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline
Annals of Internal Medicine 2019cited by 25position: middledoi
Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4–5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial
˜The œLancet. Gastroenterology & hepatology 2017cited by 76position: middledoi
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study
The Lancet 2015cited by 665position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Stanislas Pol · Groupe Hospitalier Cochin - Port-Royal, Hôtel-Dieu, Broca - La Collégiale3 papers (2015–2019)Paul Martin · University of Miami3 papers (2015–2019)Annette Bruchfeld · Linköping University2 papers (2015–2017)Howard Monsour · Methodist Hospital2 papers (2015–2017)David Roth · University of Miami2 papers (2015–2017)María‐Carlota Londoño · Centre for Biomedical Network Research on Rare Diseases2 papers (2015–2017)David R. Nelson · New York University Abu Dhabi2 papers (2015–2017)Michael Robertson · Merck & Co., Inc., Rahway, NJ, USA (United States)2 papers (2015–2017)Eliav Barr · Merck & Co., Inc., Rahway, NJ, USA (United States)2 papers (2015–2017)Janice Wahl · Merck & Co., Inc., Rahway, NJ, USA (United States)2 papers (2015–2017) · 2 papers (2015–2017) · 2 papers (2015–2017) · 1 papers (2019–2019)Philippe J. Zamor · Atrium Health Wake Forest Baptist1 papers (2015–2015)Priti R. Patel · University of Maryland, College Park1 papers (2019–2019)Michel Jadoul · UCLouvain1 papers (2019–2019)Vivekanand Jha · Rajamangala Institute of kidney disease1 papers (2019–2019)Tarek Hassanein · Retina Research Foundation1 papers (2015–2015)Nassim Kamar · French Clinical Research Infrastructure Network1 papers (2019–2019)Michael Cheung · Royal Children's Hospital1 papers (2019–2019)